DatChem’s deep data technology platform, developed in tandem with Siemens is a clinically validated, datamining-powered software that utilises magnetic resonance spectroscopy (MRS) (MRI machine) to identify chemical dysregulation linked to the progression of cancer and disease. 

 

The Company’s lead product is BreastPredict, cloud-based software that data mines breast chemistry via a 10–15 minute scan in a standard 3T MRI scanner, reporting on pre-cancerous dysregulation and the risk of an occult breast cancer being present before a lesion is visible using current imaging.

 

DatChem's technology platform includes a strong pipeline of late-stage diagnostics across women’s health and neurological diseases.